Fortress Biotech, Inc. Annual report pursuant to Section 13 and 15(d)

Net Loss Per Common Share (Tables)

Net Loss Per Common Share (Tables)

12 Months Ended

Dec. 31, 2013

Calculation of Basic and Diluted Net Loss Per Share

A calculation of basic and diluted net loss per share follows:

	For the year ended December 31,
	2013		2012		2011
($ in thousands except share and per share amounts)
Historical net loss per share:
Numerator
Net loss	$	(37,158)	$	(27,610)	$	(36,360)
Common stock dividend to Series A Preferred stockholders						(5,861)
Net loss attributed to Common stockholders	$	(37,158)	$	(27,610)	$	(42,221)

Denominator
Weighted-average common shares outstanding Denominator for basic and diluted net loss per share		30,429,743		21,654,984		7,662,984
Basic and diluted net loss per share attributed to common stockholders	$	(1.22)	$	(1.27)	$	(5.51)

Computations of Diluted Weighted Average Shares Outstanding

The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as the effect of including such securities would be antidilutive:

	For the year ended December 31,
	2013	2012	2011
Series A Shares			3,796,733
Series B Shares			2,158,935
Series C Shares			1,966,635
Unvested restricted Common stock
Warrants to purchase Common stock	1,012,977	1,091,558	804,949
Options to purchase Common stock	3,936,199	2,279,603	1,479,291
Restricted Stock	140,995
	5,090,171	3,371,161	10,206,543